[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:tnfrsf8-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"TNFRSF8 Gene",11,10,[8,16,23,29,35,42,48,54,60,66,72],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",[12],"Phase 1","RECRUITING","2026-08-26T02:17:13.277148Z","2026-05-29T15:36:40.172598Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06377566","A Study of BV-AVD in People With Bulky Hodgkin Lymphoma",[20],"Phase 2","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.352411Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04083495","CD30 CAR for Relapsed\u002FRefractory CD30+ T Cell Lymphoma",[20],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:29.068613Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04587687","Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.811399Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06090864","ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells",[39],"Phase 1\u002FPhase 2","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.510158Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT03007030","Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery",[20],"2026-08-03T03:20:51.997416Z","2026-05-05T02:43:27.514628Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05313243","Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed\u002FRefractory T-cell Lymphoma",[20],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:27.391034Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05357794","Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides",[20],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:27.245802Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04745949","PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy",[20],"2026-08-26T02:19:27.519777Z","2026-04-29T02:57:57.080381Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07283822","Amping up With PemJAK",[20],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":73,"title":74,"phases":75,"status":76,"updated_at":77,"content_modified":78},"NCT06617286","CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma",[39],"NOT_YET_RECRUITING","2026-08-26T02:16:11.347936Z","2026-05-05T02:43:29.693368Z"]